These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32200201)

  • 21. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
    Li W; Li X; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2015 Sep; 102():167-79. PubMed ID: 26276432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1.
    Costa CCP; Boechat N; Bastos MM; da Silva FC; Marttorelli A; Souza TML; Baptista MS; Hoelz LVB; Cafffarena ER
    Curr Top Med Chem; 2018; 18(17):1494-1505. PubMed ID: 30370848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.
    Frączek T; Kamiński R; Krakowiak A; Naessens E; Verhasselt B; Paneth P
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):9-16. PubMed ID: 29098886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
    Huang B; Li C; Chen W; Liu T; Yu M; Fu L; Sun Y; Liu H; De Clercq E; Pannecouque C; Balzarini J; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 92():754-65. PubMed ID: 25626145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
    Kang D; Urhan Ç; Wei F; Frutos-Beltrán E; Sun L; Álvarez M; Feng D; Tao Y; Pannecouque C; De Clercq E; Menéndez-Arias L; Liu X; Zhan P
    Eur J Med Chem; 2021 Dec; 225():113769. PubMed ID: 34403976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.
    Huang WJ; Pannecouque C; De Clercq E; Wang S; Chen FE
    Eur J Med Chem; 2024 Oct; 276():116668. PubMed ID: 38996652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Jan; 185():111874. PubMed ID: 31735575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
    Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A
    Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Wu HQ; Yao J; He QQ; Chen WX; Chen FE; Pannecouque C; De Clercq E; Daelemans D
    Bioorg Med Chem; 2015 Feb; 23(3):624-31. PubMed ID: 25537532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach.
    Li X; Chen W; Tian Y; Liu H; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Eur J Med Chem; 2014 Jun; 80():112-21. PubMed ID: 24769349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.
    Urano E; Miyauchi K; Kojima Y; Hamatake M; Ablan SD; Fudo S; Freed EO; Hoshino T; Komano J
    ChemMedChem; 2016 Oct; 11(20):2320-2326. PubMed ID: 27634404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Searching for novel scaffold of triazole non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Frączek T; Paneth A; Kamiński R; Krakowiak A; Paneth P
    J Enzyme Inhib Med Chem; 2016; 31(3):481-9. PubMed ID: 25942362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
    Liu Z; Chen W; Zhan P; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Nov; 87():52-62. PubMed ID: 25240095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
    Zhan P; Chen X; Li X; Li D; Tian Y; Chen W; Pannecouque C; De Clercq E; Liu X
    Eur J Med Chem; 2011 Oct; 46(10):5039-45. PubMed ID: 21872971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.
    Xu S; Song S; Sun L; Gao P; Gao S; Ma Y; Kang D; Cheng Y; Zhang X; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
    Bioorg Med Chem; 2022 Jan; 53():116531. PubMed ID: 34890994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors.
    Fang Z; Kang D; Zhang L; Huang B; Liu H; Pannecouque C; De Clercq E; Zhan P; Liu X
    Chem Biol Drug Des; 2015 Oct; 86(4):614-8. PubMed ID: 25626467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Liu N; Qin B; Sun LQ; Yu F; Lu L; Jiang S; Lee KH; Xie L
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3719-23. PubMed ID: 25042339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
    Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
    Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.